FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Chugai Pharmaceutical

Gene Bridges Licenses Recombineering Technology to Chugai Pharmaceutical Co., Ltd.

02-Jun-2009 - Gene Bridges GmbH announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan ...

chromosomes Daiichi Sankyo DNA cloning +2

OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan

19-Apr-2006 - OSI Pharmaceuticals, Inc. announced that a New Drug Application has been submitted in Japan covering the use of its flagship product, Tarceva(R) (erlotinib), for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). The application was submitted to the Japanese Ministry of ...

chemotherapy Japan lung cancer +1

Cambrex Licenses Cell Line to Chugai Pharmaceutical Co.

23-Feb-2006 - Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex, announced that its client Chugai Pharmaceutical Co., Ltd. completed their assessment of certain of its Clonetics(R) Conditionally Immortalized Cell Lines under the previously announced evaluation license and signed a one-year ...

cell lines Japan license agreements +2

Collaborative Search for Microorganisms in Vietnam

03-Nov-2005 - The National Institute of Technology and Evaluation (NITE), Astellas Pharma Inc. and Chugai Pharmaceutical Co., Ltd. will start the first industry-government collaborative research program in November to jointly search, collect and isolate microorganisms in Vietnam and assess their potential for ...

Astellas Pharma microbes microbiology +2

Cambrex Licenses Cell Lines to Chugai Pharmaceutical Co.

05-Oct-2005 - Cambrex Bioscience Walkersville, Inc., a subsidiary of Cambrex Corporation, announced that they have signed an evaluation license agreement with Chugai Pharmaceutical Co., Ltd. for the use of certain Cambrex Clonetics® Conditionally Immortalized Cell Lines. The licensed cell lines were created ...

cardiovascular diseases cell lines cell-based assays +5